14  Clinical Trials in MDS

15 IRAK 1/4 inhibitors

15.2 R289

  • R289 (an oral prodrug that is rapidly converted to R835 in the gut)
  • A Phase 1b open-label, multicenter trial of R289 in patients with relapsed/refractory lower-risk MDS is currently enrolling.

16 Lisaftoclax

  • Ascentage Pharma
  • BCL2 selective inhibitor ## GLORA-4 clinical trial